ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Author Affiliations: Reference center for neuromuscular disorders and ALS, University Hospital la Timone, Marseille, France; Department of Neurology, University Medical Center Göttingen, Germany; Institute for Sleep Medicine and Neuromuscular Disorders, Muenster University Hospital, Münster, Germany; Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen Switzerland; Reference Center for ALS and other Motoneuron Disorders, University Hospital Bretonneau, Tours, France; Department of Neurology, Technical University of Munich, Munich, Germany; Department of Neurology, Technical University of Munich, Munich, Germany; Department of Neurology, Alfried Krupp Hospital, Essen, Germany; Department of Neurology, Jena University Hospital, Jena, Germany; Department of Neurology, Technical University of Dresden, Dresden, Germany; German Center for Neurodegenerative Diseases (DZNE) Dresden, Dresden, Germany; Department of Neurology, University Medical Center Göttingen, Germany; Department of Neurology, University Medical Center Göttingen, Germany; Department of Neurology, University Medical Center Göttingen, Germany; Center for ALS and other motor neuron disorders, Charité–Universitätsmedizin Berlin, Germany; Department of Neurology, Hannover Medical School, Hannover, Germany; Pharmacy at the University of Leipzig Medical Center, Leipzig, Germany; Department of Neurology, University Medical Center Göttingen, Germany; Department of Neurology, University of Ulm, Ulm, Germany; Center for ALS, University Hospital Pasteur, CHU de Nice, France; University of Kansas Medical Center, Kansas City, KS, United States; Department of Neurology, University of Ulm, Ulm, Germany; Department of Neurology, University of Würzburg, Würzburg, Germany; Department of Neurology, University Medical Center Göttingen, Germany.

[1] ¹Department of Neurology, Technical University of Munich , Munich, Germany

[2] ²Department of Neurology, University Medical Center Göttingen , Göttingen, Germany

[3] ³Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. , Gallen, Switzerland

[4] ⁴Reference Center for ALS and Other Rare Motoneuron Disorders, University Hospital Gui de Chauliac , Montpellier, France

[5] ⁵Department of Medical Statistics, University Medical Center Göttingen , Göttingen, Germany

[6] ⁶Department of Neurology, Technical University of Dresden , Dresden, Germany

[7] ⁷German Center for Neurodegenerative Diseases (DZNE) Dresden , Dresden, Germany

[8] ⁸Department of Neurology, University of Miami , Miami, FL, United States

[9] ⁹Department of Neurology, Medical University of Warsaw , Warsaw, Poland

[10] ¹⁰Münchner Studienzentrum, Technical University of Munich , Munich, Germany

[11] ¹¹Pharmacy at the University of Leipzig Medical Center , Leipzig, Germany

[12] ¹²Department of Neurology, University of Ulm , Ulm, Germany